Mycophenolate Pregnancy Registry
This registry is observing how mycophenolate (CellCept, Myfortic, and generic versions) affects pregnancy outcomes. It's for women who have been exposed to mycophenolate during pregnancy or within 6 weeks before becoming pregnant. The goal is to understand the rate of pregnancy complications for mothers and birth defects in babies, and how long mothers were exposed to the medication. This is an ongoing registry, and it's part of a safety plan required by the FDA.
- Study design
- This is an observational registry, meaning researchers will collect information without giving any specific treatments. It aims to include 500 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for approximately 13 years to track maternal and fetal outcomes, and the duration of mycophenolate exposure.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Mycophenolate Pregnancy Registry
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Clinical Trials · STUDY_DIRECTOR · Genentech, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Maternal Outcomes: Incidence of Pregnancy ComplicationsApproximately 13 years
- Fetal Outcomes: Incidence of Congenital DisordersApproximately 13 years
- Time/Duration of Mycophenolate ExposureApproximately 13 years
- Mycophenolate Dose/RegimenApproximately 13 years
- Indications for Mycophenolate useApproximately 13 years
- Maternal Medical/Demographic CharacteristicsApproximately 13 years